GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Cash Flow from Financing

Consun Pharmaceutical Group (HKSE:01681) Cash Flow from Financing : HK$-782 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Consun Pharmaceutical Group received HK$124 Mil more from issuing new shares than it paid to buy back shares. It spent HK$275 Mil paying down its debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent HK$246 Mil paying cash dividends to shareholders. It spent HK$12 Mil on other financial activities. In all, Consun Pharmaceutical Group spent HK$409 Mil on financial activities for the six months ended in Dec. 2024.


Consun Pharmaceutical Group Cash Flow from Financing Historical Data

The historical data trend for Consun Pharmaceutical Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Cash Flow from Financing Chart

Consun Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -331.69 -204.07 -382.15 -306.37 -778.61

Consun Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.64 -150.44 -155.92 -367.95 -413.69

Consun Pharmaceutical Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Consun Pharmaceutical Group's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Consun Pharmaceutical Group's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-782 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Consun Pharmaceutical Group  (HKSE:01681) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Consun Pharmaceutical Group's issuance of stock for the six months ended in Dec. 2024 was HK$124 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Consun Pharmaceutical Group's repurchase of stock for the six months ended in Dec. 2024 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Consun Pharmaceutical Group's net issuance of debt for the six months ended in Dec. 2024 was HK$-275 Mil. Consun Pharmaceutical Group spent HK$275 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Consun Pharmaceutical Group's net issuance of preferred for the six months ended in Dec. 2024 was HK$0 Mil. Consun Pharmaceutical Group paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Consun Pharmaceutical Group's cash flow for dividends for the six months ended in Dec. 2024 was HK$-246 Mil. Consun Pharmaceutical Group spent HK$246 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Consun Pharmaceutical Group's other financing for the six months ended in Dec. 2024 was HK$-12 Mil. Consun Pharmaceutical Group spent HK$12 Mil on other financial activities.


Consun Pharmaceutical Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
Fmr Llc 2201 Interest of corporation controlled by you
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Gl China Long Equity Opportunities Fund Lp 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
An Meng 2101 Beneficial owner
Zhang Lihua 2202 Interest of your spouse
Double Grace International Limited 2101 Beneficial owner
Li Qian 2101 Beneficial owner
An Yubao 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group Headlines

No Headlines